

# The Education Pages

Current CEU's, CME's and continuing education opportunities

## Continuing Education Opportunities

The following continuing education activities are presented by Abraxis Oncology, Amgen and Millennium Pharmaceuticals, Inc.

### **NANOTECHNOLOGY: NEW DEVELOPMENTS FOR BREAST CANCER TREATMENT**

CE ID: 3114

Register online at: [www.oesweb.com](http://www.oesweb.com)

Expiration date: August 22, 2007

**Program Overview:** What is nanotechnology? Nanotechnology is exciting new clinical science that uses atoms and molecules to develop incredible new opportunities in cancer care. This session will use keypad technology and small group discussion to unravel breast cancer case studies. This program will deliver current, evidenced-based information on nanotechnology and targeted delivery systems for chemotherapy.

**Target Audience:** This program is intended for oncology nurses interested in learning the latest information pertaining to the use of nanotechnology for the patient with breast cancer.

**Continuing Education Information:** This program has been approved for **1.8 contact hours** by the Oncology Nursing Society (ONS) Approver Unit. ONS is accredited as an approver of continuing education in nursing by the American Nurses Credentialing Center's Commission on Accreditation. This session includes approximately 25 minutes of pharmacology content.

This educational program has been developed and produced by Oncology Education Services, Inc. (OES), through an unrestricted grant from Abraxis Oncology.

### **ONCOLOGY SUPPORTIVE CARE QUARTERLY: DOSE DENSITY**

**Focused on Nursing Issues in the Care of Oncology Patients: Volume 2, Issue 2**

Contact hours: 2.2 contact hours

CE ID: 2474

Expiration Date: December 15, 2005

Registration: [www.oesweb.com](http://www.oesweb.com)

Sponsored by an educational grant from Amgen, Inc.

### **ONCOLOGY SUPPORTIVE CARE QUARTERLY: TREATMENT MODALITIES**

**Focused on Nursing Issues in the Care of Oncology Patients: Volume 2, Issue 3**

Contact hours: 1.9 contact hours

CE ID: 2616

Expiration Date: April 1, 2006

Registration: [www.oesweb.com](http://www.oesweb.com)

Sponsored by an educational grant from Amgen, Inc.

### **CASE STUDIES IN LYMPHOMA**

**June 2005, Vol. 3, No. 4; 1 AMA PRA Category 1 Credit**

Release date: June 30, 2005

Expiration date: June 30, 2006

Registration: visit [www.cancerpublications.com](http://www.cancerpublications.com) to download the full publication.

#### **Learning Objectives:**

- > Discuss the impact on efficacy of adding an anti-CD20 antibody to CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone)-like chemotherapy in mantle cell lymphoma
- > Evaluate the efficacy and safety of proteasome inhibitors in the treatment of mantle cell lymphoma

Case Studies in Lymphoma is produced by Physicians' Education Resource, Dallas, TX. An unrestricted educational grant for this publication was provided by Millennium Pharmaceuticals, Inc.